Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGC101 in Critical Limb Ischemia
NCT02805023Phase 2Active, not recruiting
- Sponsor
- BioGenCell
- Start
- Jun 2016
- Primary completion
- Jul 2017
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
A Phase 2 trial of BGC101 in critical limb ischemia (CLI), sponsored by BioGenCell. Started Jun 2016; status: active, not recruiting.
02
Drugs
BGC101
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02805023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805023.